Member Info for fundraiser222

Yes matd was very nice indeed from those 2p days, I Knew Evg would re rate quickly it’s more tightly held than matd and has a tiny free float, CEO is also top notch and this is his brain child

Your welcome mate, re rate is on

Think we could see an all time record volume day today here which is long overdue, staggering potential imo

$6bn market revenue opportunity for the two current phase 2 trials with the SAS trial already been granted orphan drug designation. SFX-01 also has the opportunity to be used in Austism, MS, arthritis and lots of different cancers... so from a £12m mcap and broker target of 97p I cannot see a better share on aim for blue sky multibag potential for 2018. Short term catalysts with interim results due in next few weeks with full trial update. Q1 breast cancer interim trial readout will multibag it alone if positive but we should be around ipo price of 37p as we move into late December the market has completely missed this one a transformational few months ahead staggering potential that’s for sure With the breast cancer trial already granting a compassionate use program to the first patient dosed with SFX-01 who showed no disease progression after 6 months of using the drug..... good luck all an exciting few weeks and months ahead

Should get there very quickly as we look forward to interim results in next few weeks, also worth noting that from 20p downwards for the last 3 months I have been pretty much the only buyer as it has been so far off the radar so there won’t be many sellers at all I would t have thought, q1 breast cancer interim data readout if positive could easily see this hit broker target of 97p then if full readout is positive and the SAS trial is positive we are talking mcap in the hundreds of millions due to the multi billion dollar revenue potential of SFX-01

Hundreds of hours of research have gone into this mate from my side I have red everything there is to read over the last 2 years, the broker comments below are interesting and show just how undervalued Evgen is https://vimeo.com/199799245

Your welcome eyeguy it was completely missed by the market and should re rate back to the ipo price of 37p very quickly once ppl research the potential as it is truely epic, all uk based management are all based in Manchester institutional investors such as AXA on the share register 28% free float and most investors in at 37p recently tipped by Sunday times and they know their stuff, it’s a little cracker and looks like 37p ipo price is imminent as we await the interim results

This moves so fast on any buying pressure, imagine what it will do on multi million buying volume could easily do 500% in a day if the breast cancer interim trial readout in q1 is positive as the market for the drug for use in breast cancer is stated to be $4.1bn!! And lots of other cancers can also be treated with SFX-01 if it is proven to work in breast cancer the potential here is just epic and with a major pharma already known to have tried to buy Evg before there ipo at 37p interest will be very strong for a buyout. If you listen to the ceo talking through the final results in June he states he is already talking to potential partners.... I have spent hundreds of hours researching this share and believe it to be imo the best blue sky potential share on aim due to its multi billion dollar revenue potential

$6bn market revenue opportunity for the two current phase 2 trials with the SAS trial already been granted orphan drug designation. SFX-01 also has the opportunity to be used in Austism, MS, arthritis and lots of different cancers... so from a £12m mcap and broker target of 97p I cannot see a better share on aim for blue sky multibag potential for 2018. Short term catalysts with interim results due in next few weeks with full trial update. Q1 breast cancer interim trial readout will multibag it alone if positive but we should be around ipo price of 37p as we move into late December the market has completely missed this one but luckily I havnt and neither have the hand full of posters here a transformational few months ahead staggering potential that’s for sure With the breast cancer trial already granting a compassionate use program to the first patient dosed with SFX-01 who showed no disease progression after 6 months of using the drug..... good luck all an exciting few weeks and months ahead

Some very well known tipsters and investors have started to take a position here today it seems and I’m not surprised as a bit of research tells you straight away that this is worth multiples of the current price given the potential and the news flow throughout 2018, if the interim breast cancer trial readout is positive the 97p broker target will be hit very quickly indeed, imm raced from 25p to 100p as the trial results draw closer I expect Evg to follow that trend and at least 4 bag leading up to results

And the fundamentals shine through eventually, it’s just a matter of making peeps aware of the fundamentals so they can research them for themselves but any investor worth their salt will see the multibag potential here

Yes it is a complete no brainer and has been completely missed by the market, I am speaking with a lot of investors about this stock and they are stunned as to how low the price has fallen given its potential, the chart is looking great and with the majority of shares bought in the ipo at 37p it could easily be trading back at 37p very soon the buys at 20p and below for the last 3 months are mainly mine believe me but a long long way to go and best to be in Early and hold if you want to see life changing gains

Nice to see you on board earthling, the potential is huge I have spent the past 2 years researching this share and the last 3 months buying a large holding at a 16p average, this price is crazy cheap and it has only got here because it is completely off the radar... but it won’t be off the radar forever, I have been got Jim Mellon to take a look so be interesting to hear his thoughts he says on Twitter that he will take a look, can see some large positions been taken as buying Early is key as it moves very fast on any buying, happy to share my research and no doubt the board will start to get busy over the weeks and months ahead

Fully agree rift £10m mcap and 14.5p is ridiculously low this hit 44p Intraday when it listed and since then they have released nothing but positive updates no share dilution and 2018 will Imo price to be a transformational year for Evg and it’s share price, £100m mcap is not unrealistic if the breast cancer interim data readout in q1 is positive given the $4bn size of the market for the drug, and all signs so far are that it will be positive given they have initiated a compassionate use program as the first patient has had no cancer progression after 24 weeks, after speaking with lots of successful investors about this share the feedback has been very positive indeed and I would not be surprised if a few of them start to take positions over the next few weeks with interim results due in December, last 2 interim results were released first Monday in December so we are very close to news and imo the share price will be around the ipo price of 37p when news is announced

Babbler are you still in Evg?

Fully agree, a big pharma tried to buy Evgen before they did the ipo and the ceo has stated in his June interview that he is in active dialogue with partners and they are looking forward to the readout of the trials, imm has £130m mcap and is targeting a market smaller revenue wise than Evg yet Evg has an mcap of £10m.... interims should see it back into the 20’s and the breast cancer interim trial readout in q1 if positive should see it multibag very quickly, best time to buy is when no one else is watching

Nice to have you on board rift, it will no doubt be me and you talking to each other at this all time low level just like it was in matd below 3p.... anyone who research’s this share properly will be blown away by the potential, we have orphan designation for the SAS trial so if results are positive in 2018 the drug can be fast tracked to be sold into a market worth $1.7bn per year in revenue, Breast cancer has $4.1bn market potential and will report at the half way point in q1 2018 so in a few months time and we have a full update in the interims due in next few weeks, if this doesn’t multibag in the next few months I will be gobsmacked

This really is an excellent opportunity to load up at all time lows before the interims are announced 50% profit alone when it gets back to 21p and huge multibag potential going forward I just can’t belive the market has missed this one

Mainly to buy more Evgen Pharma as it is at all time lows and ridiculously undervalued for its potential, but happy to hold my remaining avo and hoping so a few more presentations pharma companies need to be more active on the pr side

So $6bn market opportunity for the two current trials alone and SFX-01 also has the opportunity to be used in Austism, MS, arthritis and lots of different cancers... so from a £10m mcap at 14.25p and broker target of 97p I cannot see a better share on aim for blue sky multibag potential for 2018. Short term catalysts with interim results due in next few weeks with full trial update. Q1 breast cancer interim trial readout will multibag it alone if positive but we should be around ipo price of 37p as we move into q1, the market has completely missed this one but luckily I havnt and neither have the hand full of posters here a transformational few months ahead staggering potential